Regimen Reference Order – GAST – octreotide LAR

Planned Course: **Every 28 days until disease progression or unacceptable toxicity**
Indication for Use: **Neuroendocrine tumors (NET)**

CVAD: Not Required

Proceed with treatment if:

- ***Blood work not required***

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST – octreotide LAR

Drug	Dose	CCMB Administration Guideline
octreotide long acting release	30 mg	Deep intramuscular injection – alternating right and left intragluteal muscle **Nursing Alert: refer to package insert for reconstitution instructions; once suspended in diluent, should be used immediately*

In the event of a hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order**'

REQUIRED MONITORING

Every 3 months

- CBC, urea, creatinine, electrolytes, liver function tests, as per physician order

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- octreotide LAR vials must be stored in the fridge between 2 to 8 degrees Celsius and kept in the carton in order to protect it from light

ADDITIONAL INFORMATION

- Prior to first dose of octreotide LAR, a test dose of octreotide immediate release (usual 50 mcg) is administered subcutaneously followed by an observation period, as per physician order
- For patients progressing on octreotide LAR 30 mg, may increase dose to 60 mg
- If administered in the treatment room, patient needs to bring their own supply for injection
- octreotide LAR can cause cholelithiasis and increased blood sugar